[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-4-hydroxy-3-methoxyoxolan-2-yl]methyl phosphono phosphate;N,N-diethylethanamine

((2R,3R,4R,5R)-5-(2-Amino-7-methyl-6-oxo-3,6-dihydro-9H-purin-7-ium-9-yl)-3-hydroxy-4-methoxytetrahydrofuran-2-yl)methyl hydrogen phosphate

RNA modification intermediate

2-(3-(4-Bromo-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

pharmaceutical intermediate

2-[[3,4-Dihydro-3-methyl-2,4-dioxo-6-[(3R)-3-piperidinylamino]-1(2H)-pyrimidinyl]methyl]-benzonitrile

Alogliptin impurity reference standard

8-Chloro-6-fluoroquinazoline-2,4-diol

Pharmaceutical intermediate for quinazoline derivatives

1-(bromomethyl)-1-(trifluoromethyl)cyclopentane

Pharmaceutical intermediate compound

7-methylguanosine 5'-(trihydrogen diphosphate)

Pharmaceutical intermediate for nucleotide analogs